SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: S-3
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea0266812-s3_synergy.htm

Chunk 19 of 26
Word Count: 1389
Character Count: 8465

Document Content:

sole owner of four subsidiaries: NomadChoice Pty Ltd., Hand MD Corp., Synergy CHC Inc. and Synergy CHC Mexico, and the results have been consolidated in these statements. Synergy CHC Mexico was incorporated during May 2025 for the purposes of expanding into Mexico. We completed our initial public offering on October 24, 2024, and became subject to the information and reporting requirements of the Exchange Act. We file periodic reports, proxy statements and other information with the SEC. The address of our principal executive offices is 865 Spring Street, Westbrook, Maine 04092 and our phone number is (207) 321-2350. Our website is www.synergychc.com. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus supplement. THE OFFERING Common stock offered by us: Shares of our common stock having an aggregate offering price of up to $5.69 million.

Common stock to be outstanding after the offering 13,987,429 shares of common stock, assuming the sale of the full $5.69 million worth of our common stock in this offering (which is 2,735,576
shares of common stock at an assumed sales price of $2.08 per share, which was the closing price of our common stock on the Nasdaq Capital
Market on November 20, 2025). The actual number of shares issued in this offering will vary depending on the number of shares sold in
this offering and the sales price at which shares may be sold from time to time during this offering.

Manner of offering “At the market offering” as defined in Rule 415(a)(4) under the Securities Act that may be made from time to time through our Agents. See “Plan of Distribution” on page S-13 of this prospectus supplement.

Use of Proceeds We intend to use the net proceeds from these sales for research and development expenses, working capital and other general corporate purposes, which may include funding acquisitions or investments in businesses, products or technologies that are complementary to our own and reducing indebtedness.

Risk Factors An investment in our securities is highly speculative and subject to substantial risks . You should consider the “Risk Factors” and the “Cautionary Note Regarding Forward-Looking Statements” included and incorporated by reference in this prospectus supplement, including the risk factors incorporated by reference from our filings with the SEC.

Nasdaq Capital Market symbol “SNYR”

The discussion and table above
are based on 11,251,853 shares of common stock outstanding as of November 20, 2025, and excludes the following securities as of that date:

●	excludes 1,452,102 shares of common stock issuable upon
the exercise of outstanding options at a weighted average exercise price of $3.03 per share;

●	excludes 1,052,102 shares of common stock reserved for
future issuance pursuant to the Synergy CHC Corp. 2024 Equity Incentive Plan (the “2024 Equity Incentive Plan”); and

●	excludes 156,000 shares of common stock issuable upon the
exercise of outstanding warrants at a weighted average exercise price of $8.69 per share.

RISK FACTORS

Investing in our securities
is highly speculative and involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully
consider the risk factors we describe in this prospectus supplement and the prospectus and in any related free writing prospectus that
we may authorize to be provided to you or in any report incorporated by reference into this prospectus supplement, including our Annual
Report on Form 10-K for the year ended December 31, 2024, or any Annual Report on Form 10-K or Quarterly Report on Form 10-Q that is incorporated
by reference into this prospectus supplement after the date of this prospectus supplement. Although we discuss key risks in those risk
factor descriptions, additional risks not currently known to us or that we currently deem immaterial also may impair our business. Our
subsequent filings with the SEC may contain amended and updated discussions of significant risks. We cannot predict future risks or estimate
the extent to which they may affect our financial performance.

Risks Related to This Offering

You may experience immediate and substantial dilution as a result
of this offering.

The offering price per share in this “at the market” offering program may exceed the net tangible book value per share of
our common stock. Assuming that an aggregate of 2,735,576 shares of our common stock are sold under the program at a price of $2.08 per
share pursuant to this prospectus supplement, which was the last reported sale price of our common stock on The Nasdaq Capital Market
on November 20, 2025, for aggregate proceeds of $5.5 million after deducting commissions and estimated aggregate offering expenses payable
by us, you would experience immediate dilution of $2.29 per share, representing a difference between our as adjusted net tangible book
value per share as of September 30, 2025 after giving effect to this offering and the assumed offering price. The exercise of outstanding
stock options or warrants may result in further dilution of your investment. See the section entitled “Dilution” on page S-9
of this prospectus supplement for a more detailed illustration of the dilution you would incur if you participate in this offering.

Management will have broad discretion as
to the use of the proceeds from this offering and may not use the proceeds effectively.

Because we have not designated
the amount of net proceeds from this offering to be used for any particular purpose, our management will have broad discretion as to the
application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering.
Our management may use the net proceeds for corporate purposes that may not improve our financial condition or market value.

Future sales of substantial amounts of our
common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.

We may issue up to $5.69 million
of common stock from time to time in this offering. The issuance from time to time of shares in this offering, as well as our ability
to issue such shares in this offering, could have the effect of depressing the market price or increasing the market price volatility
of our common stock. This could impair our ability to raise capital through the sale of additional equity securities.

It is not possible to predict the actual
number of shares we will sell under the sales agreement, or the gross proceeds resulting from those sales.

Subject to certain limitations
in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the Lead Agent at any
time throughout the term of the sales agreement. The number of shares that are sold through the Lead Agent after delivering a placement
notice will fluctuate based on a number of factors, including the market price of the common stock during the sales period, the limits
we set with the Lead Agent in any applicable placement notice, and the demand for our common stock during the sales period. Because the
price per share of each share sold will fluctuate during the sales period, it is not currently possible to predict the number of shares
that will be sold or the gross proceeds to be raised in connection with those sales. Further, we are not obligated to sell any shares
under the sales agreement, so you should not invest in our securities in reliance on the fact that we will actually raise new capital
via the at the market sales program covered by this prospectus supplement.

The common stock offered hereby will be
sold in an “at the market offering,” and investors who buy shares at different times will likely pay different prices.

Investors who purchase shares
in this offering at different times will likely pay different prices, and so may experience different levels of dilution and different
outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares
sold in this offering. In addition, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience
a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.

USE OF PROCEEDS